October 1, 2016. AC Immune SA closed its IPO and listing on NASDAQ of 6,900,000 shares at a price of USD 11 each, valuing the gross proceeds of the IPO at USD 75.9 m. The IPO was conducted by Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC as joint-bookrunning managers. AC Immune SA is a Swiss clinical stage biopharmaceutical company focused on neurodegenerative diseases, based in Lausanne.

Homburger acted as Swiss legal counsel to the joint managers. The Homburger team was led by partner Dieter Gericke (Corporate | M&A) and comprised counsel Peter Müller (Tax) and associate Benjamin Leisinger (Financial Services) as well as associates Dominik Aerni and Valentin Jentsch (both Corporate | M&A).